Showing results (91-100 of 259) with videos related to
Sort By:
Pageof 26
Clinical Lung Cancer|September 13, 2022
The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX)Tami J Bang, Junxiao Hu, Tejas Patil, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2016
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 StudyJames Chih-Hsin Yang, Vichien Srimuninnimit, Myung-Ju Ahn, et al.Oncotarget|February 11, 2016
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patientsShang-Gin Wu, Yi-Nan Liu, Meng-Feng Tsai, et al.European Journal of Cancer (Oxford, England : 1990)|January 12, 2025
Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective studyHsin-Yi Wang, Wei-Yu Liao, Chao-Chi Ho, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 4, 2015
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal CarcinomatosisBin-Chi Liao, Jih-Hsiang Lee, Chia-Chi Lin, et al.Cancer Medicine|March 29, 2022
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimensWei-Li Ma, Chia-Chi Lin, Feng-Ming Hsu, et al.Lung Cancer (Amsterdam, Netherlands)|December 8, 2024
Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutationsMengzhao Wang, Yan Xu, Wen-Tsung Huang, et al.Clinical Lung Cancer|February 26, 2018
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer PatientsTing-Hui Wu, Emily Han-Chung Hsiue, Jih-Hsiang Lee, et al.Journal of Hematology & Oncology|June 24, 2023
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancerCharles M Rudin, Martin Reck, Melissa L Johnson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2016
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor MutationsYing Cheng, Haruyasu Murakami, Pan-Chyr Yang, et al.Pageof 26